Scientists at the University of Oxford and AstraZeneca Plc Covid-19, are using the same technology to test the development of a therapeutic vaccine against cancer, with promising results in animal studies.
Researchers have developed a two-dose therapeutic vaccine using the technology involved in Covid-19 vaccination, scientists said in a study published in the Journal for ImmunoTherapy of Cancer Friday. The vaccine will enter human trials this year, as studies in mice showed a reduction in tumor size and improved survival rate.
Vaccine research has advanced in the wake of the pandemic as scientists and governments worked faster than ever before and with greater resources to test and find vaccines that would help curb the virus.
To create the treatment, the scientists designed their vaccine to target two MAGE-type proteins that are present on the surface of many types of cancer cells.
It is hoped that the stroke could be used in humans in conjunction with cancer immunotherapy, where the patient's T cells fight tumors.
